Ayrmid Appoints Ideogen for Omisirge(R) in EMEA
(PR-inside.com) Ayrmid Appoints Ideogen as Exclusive Partner for Omisirge® across Multiple Regions in Europe, MENA and CIS Ideogen granted exclusive rights to launch a managed access program for Omisirge across 55 markets, covering both FDA-approved Omisirge indications DUBLIN, IE / ACCESS Newswire / September 1, 2026 / Ayrmid Ltd. ("Ayrmid" or the "Company"), parent company of Gamida Cell Inc., today announced the appointment of Ideogen Group GmbH ("Ideogen") as its exclusive distributor for Omisirge® (omidubicel-onlv). Under the agreement, Ideogen is granted exclusive rights to launch a managed access program for Omisirge across 55 markets in Europe (excluding Greece and Cyprus), the Middle East ..
Read releases like this the second they cross the wire.
1,100+ feeds from 80+ newswires in one live cockpit — saved searches, instant alerts, AI summaries. 7-day free trial, no card required.
Start the free trial →Your announcement next? Distribute your press release to the global wires with PPN Source — and track its pickup live on PPN World.
PPN Source →